With over 35 years of experience in the fields of law, finance and business management, healthcare and the  healthcare and the pharmaceutical industry, Osagie is a co-founder of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical and has invested over $1 Billion in institutional money. Prior to co-founding PIPV Capital, he established GlaxoSmithKline Ventures and was its founding Vice President. Osagie has held senior commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo. He has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading US Law Firm, Schnader, Harrison, Segal & Lewis. Osagie is a serial entrepreneur and investor and serves as Chairman and Founder of Ibere Pharmaceuticals (NYSE:IBER) and Zelira Therapeutics (ASX:ZLD). He also serves on the Board of a number of financial institutions such as FS-KKR Capital Corp. (NYSE: FSK), Haverford Trust and Beltraith/StoneRidge Investment, institutions that cumulatively manage over $28 Billion. Osagie is a Trustee of the University of Pennsylvania, a member of the Executive Committee of the University, and is also the Chairman of the Board of the University of Pennsylvania Carey Law School, where he is an Adjunct Professor of Intellectual Property.

Osagie holds LLM degrees from the London School of Economics and the University of Pennsylvania Carey Law School, and is a member of the New York State Bar in addition to other Bars.